Epstein–Barr virus BamHI-A rightward frame 1 protein (BARF1) (BARF1)

The Epstein–Barr virus (EBV) BamHI-A rightward frame 1 (BARF1) protein is a secreted viral oncogene primarily expressed during the lytic cycle of EBV infection and consistently in EBV-associated malignancies such as nasopharyngeal carcinoma (NPC) and EBV-associated gastric cancer (EBVaGC). BARF1 functions as a soluble decoy receptor for colony-stimulating factor 1 (CSF-1), effectively neutralizing it to inhibit macrophage differentiation and the production of interferon-alpha, thereby facilitating viral immune evasion. Beyond its immunomodulatory role, BARF1 possesses potent oncogenic properties, including the ability to immortalize epithelial cells and inhibit apoptosis by upregulating anti-apoptotic proteins like Bcl-2. In the context of immunotherapy, BARF1-derived peptides presented on MHC Class I and II molecules serve as critical targets for T-cell mediated destruction of EBV-positive tumor cells. Because BARF1 is highly specific to EBV-infected cells and often expressed in tumors where other viral antigens like LMP1 are absent or restricted, it is a prime candidate for therapeutic vaccines and adoptive T-cell therapies (TCR-T). Research focuses on identifying immunodominant epitopes, such as the HLA-A2-restricted VLPKNVLII peptide, to enhance the precision of treatments for EBV-driven cancers while minimizing off-target effects on healthy tissues.

Other names

EBV BARF1BamHI-A rightward frame 1Soluble CSF-1 receptor homologvCSF-1REBV-encoded hexameric secreted protein

Therapeutic strategies targeting BARF1-derived peptides presented on MHC molecules typically involve the induction or adoptive transfer of antigen-specific T cells. CD8+ T cells recognize BARF1 peptides on MHC Class I to induce direct lysis of infected or malignant cells, while CD4+ T cells recognize peptides on MHC Class II to coordinate broader immune responses and provide help for B cell and CD8+ T cell activation.